[144] Apellis Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Apellis Pharmaceuticals (APLS) filing a Form 144 shows a proposed sale of 93,276 shares of common stock for an aggregate market value of $2,140,917.00, to be executed through Stifel Nicolaus & Company on Nasdaq on 09/19/2025. The shares were acquired in three tranches: 62,441 shares on 08/21/2013, 31,478 shares on 12/24/2015, and 6,081 shares on 08/07/2017; all were paid in cash to the issuer. The filer reports no securities sold in the past three months and affirms no undisclosed material adverse information.

Positive

• Full disclosure of proposed sale including broker, execution date, share count, and aggregate value
• Acquisition history provided showing long-held shares (2013–2017) paid in cash to the issuer
• No securities sold in past three months, reducing signs of accelerated liquidation

Negative

• None.

Insights

Securities Analyst

TL;DR Routine insider notice of a proposed sale: moderate size, no recent sales, not necessarily material to company fundamentals.

The Form 144 notifies the SEC of a proposed sale by an insider or affiliate totaling 93,276 shares valued at about $2.14 million. Sales will be brokered by Stifel on Nasdaq on 09/19/2025. The holdings were acquired over 2013–2017 and paid in cash to the issuer, indicating long-standing ownership rather than recent option exercises. Absence of sales in the past three months reduces concerns about an accelerated disposition program. This filing is transactional and does not disclose operational or financial performance changes.

Corporate Governance Expert

TL;DR Compliance disclosure appears complete for a Rule 144 sale; no red flags from the filing alone.

The filer attests they are unaware of undisclosed material adverse information and provides acquisition dates and payment nature for the shares. The form includes broker and execution date details, meeting standard Rule 144 notice requirements. There is no indication of a 10b5-1 plan adoption date, and no prior three-month sales are reported. From a governance perspective, the document satisfies routine transparency expectations for insider dispositions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	93276	2140917.00	126289910	09/19/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	08/21/2013	Owned Shares	Issuer			62441	08/21/2013	Cash
Common Stock	12/24/2015	Owned Shares	Issuer			31478	12/24/2015	Cash
Common Stock	08/07/2017	Owned Shares	Issuer			6081	08/07/2017	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Apellis's (APLS) Form 144 report?

The form reports a proposed sale of 93,276 shares valued at $2,140,917.00 to be executed via Stifel on Nasdaq on 09/19/2025.

Who is the broker handling the sale in the APLS Form 144?

The broker named is Stifel Nicolaus & Company Inc located at 501 N Broadway, St. Louis, MO.

When were the shares being sold originally acquired?

The shares were acquired in three tranches: 08/21/2013 (62,441), 12/24/2015 (31,478), and 08/07/2017 (6,081).

Did the filer sell any Apellis securities in the past three months?

The filing states Nothing to Report for securities sold during the past three months.

Does the Form 144 indicate undisclosed material information?

The filer signs a representation that they do not know of any material adverse information not publicly disclosed.